As genetic variation influences outcome after aSAH in humans this may translate to other conditions, such as intracerebral haemorrhage, where NRF2 may also be a promising therapeutic target to improve outcome, building on the body of animal evidence available [45]. This evidence concerns the gene NFE2L2 and intracerebral hemorrhage.